@prefix : <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis> .

<http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis> rdf:type owl:Ontology ;
                                                                                          owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                                                      mp: ;
                                                                                          rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255515/"^^xsd:anyURI ;
                                                                                          rdfs:label "Tocilizumab - Psoriasis and Aggravated psoriasis"^^rdfs:Literal ;
                                                                                          owl:versionInfo "draft-v0.95-20211112"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Data properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content
OpenPVSignal:has_content rdfs:subPropertyOf owl:topDataProperty .


###  http://www.w3.org/2006/time#nominalPosition
<http://www.w3.org/2006/time#nominalPosition> rdfs:subPropertyOf owl:topDataProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisAggPsoriasisDosage1
:AggPsoriasisDosage1 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :tocilizumab ;
                     OpenPVSignal:refers_to_interval_between_administrations :month_interval ;
                     OpenPVSignal:has_dosage_unit "mg" ;
                     OpenPVSignal:has_value 880 ;
                     OpenPVSignal:refers_to_dose_value "880 mg" ;
                     rdfs:label "Agg Psoriasis Dosage 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisAggPsoriasisDosage2
:AggPsoriasisDosage2 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :tocilizumab ;
                     OpenPVSignal:refers_to_interval_between_administrations :month_interval ;
                     OpenPVSignal:has_dosage_unit "mg/kg" ;
                     OpenPVSignal:has_value 8 ;
                     OpenPVSignal:refers_to_dose_value "8 mg/kg" ;
                     rdfs:label "Agg Psoriasis Dosage 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisAggPsoriasisDosage3
:AggPsoriasisDosage3 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :tocilizumab ;
                     OpenPVSignal:has_dosage_unit "mg" ;
                     OpenPVSignal:has_value 760 ;
                     OpenPVSignal:refers_to_dose_value "760 mg" ;
                     rdfs:label "Agg Psoriasis Dosage 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisAggPsoriasisDosage4
:AggPsoriasisDosage4 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :tocilizumab ;
                     OpenPVSignal:has_dosage_unit "mg" ;
                     OpenPVSignal:has_value 400 ;
                     OpenPVSignal:refers_to_dose_value "400 mg" ;
                     rdfs:label "Agg Psoriasis Dosage 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisAggPsoriasisDosage7
:AggPsoriasisDosage7 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :tocilizumab ;
                     OpenPVSignal:has_dosage_unit "mg" ;
                     OpenPVSignal:has_value 800 ;
                     OpenPVSignal:refers_to_dose_value "800 mg" ;
                     rdfs:label "Agg Psoriasis Dosage 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisAggPsoriasisDosage8
:AggPsoriasisDosage8 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :tocilizumab ;
                     OpenPVSignal:has_dosage_unit "mg" ;
                     OpenPVSignal:has_value 800 ;
                     OpenPVSignal:refers_to_dose_value "800 mg" ;
                     rdfs:label "Agg Psoriasis Dosage 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisBullous_pemphigoid
:Bullous_pemphigoid rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10006567 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Bullous pemphigoid" ;
                    rdfs:label "bullous pemphigoid" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisDiscussion_and_Conclusion
:Discussion_and_Conclusion rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Conclusion ,
                                    OpenPVSignal:Discussion ;
                           mp:references :ref10 ,
                                         :ref13 ,
                                         :ref6 ,
                                         :ref9 ;
                           OpenPVSignal:has_content """The reports in VigiBase do not overlap with published reports (Table 3) and provide additional information. Published articles 1 and 2 in Table 3 indicate recovery when tocilizumab was discontinued, one with recurrence on rechallenge. ICSR 3 in Table 1 indicates recovery on discontinuation and ICSR 9 in the same table notes recurrence with each tocilizumab administration. These provide support for causality. Timing of report submission to national centres with respect to when tocilizumab was discontinued is not clear in some cases so that, for the two patients (Table 2) who had not recovered when tocilizumab was discontinued, sufficient time may not have elapsed for the psoriasis to resolve when the report was submitted. The third report in Table 3 together with ICSR numbers 5 and 8 in the psoriasis group indicate that the patients recovered while tocilizumab was continued, one with topical corticosteroid treatment.
The morphology of psoriasis occurring in association with biologic anti-rheumatic agent use is also of interest. The vast majority of published cases of biologic DMARD-associated psoriasis have occurred with the TNF inhibitors. Analyses of case reports in the US FDA adverse events reporting system (AERS) database and the British Society for Rheumatology Biologics Register (BSRBR) have provided information about the characteristics of these reports.6,9 In the FDA series of reports of patients taking a TNF inhibitor for non-psoriatic indications about 17% of patients developed palmoplantar and 15% pustular psoriasis.
Palmoplantar pustular psoriasis predominated in the BSRBR reports, and guttate psoriasis was also reported. When the VigiBase ICSRs are combined with the published tocilizumab reports, 8 of the 24 ICSRs (33%) describe pustular, palmoplantar or guttate psoriasis. Assuming that the remainder of the patients developed generalised plaque psoriasis (as the nature of their psoriasis was not described), the proportion of patients with other types of lesions with tocilizumab is greater than the 20% expected for psoriasis in general, although a larger case series would be needed to confirm this.
The mechanism whereby TNF inhibitors and tocilizumab might induce or aggravate psoriasis is unknown. Clearly this is a paradoxical reaction as these medicines inhibit the actions of pro- inflammatory cytokines. IL-6 appears to have a role in maintaining inflammation in psoriasis which includes promoting TNF and other cytokine production from T helper 17 cells which are important mediators in autoimmune diseases and host defence against extracellular pathogens.10 However, as there is evidence for abatacept and limited evidence for rituximab and anakinra causing psoriasis and these are biologic anti-rheumatic agents with various effects on the immune system,13 a specific mechanism related to TNF and IL-6 inhibition is less likely. Cytokine imbalance has been proposed as a possible mechanism.10 The number of published and VigiBase ICSRs of psoriasis occurring in association with TNF inhibitors far outweighs those for tocilizumab and the other biologic anti-rheumatic agents. This may partly reflect usage and the novelty of the discovery of this reaction with TNF inhibitors leading to a greater likelihood of reporting, but further study to ascertain if there is a real difference between the agents with respect to this adverse reaction would be clinically useful. For tocilizumab the published and VigiBase spontaneous reports do suggest a possible causal relationship with the emergence or aggravation of psoriasis.""" ;
                           rdfs:label "Discussion and Conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisDr_Ruth_Savage
:Dr_Ruth_Savage rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Author ;
                OpenPVSignal:has_first_name "Ruth" ;
                OpenPVSignal:has_last_name "Savage" ;
                rdfs:label "Dr Ruth Savage" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisIC025ForTocilizumabAndPsoriasis
:IC025ForTocilizumabAndPsoriasis rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                 OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                                 OpenPVSignal:refers_to_drug :tocilizumab ;
                                 OpenPVSignal:refers_to_information_component :ICForTocilizumabAndPsoriasis ;
                                 OpenPVSignal:has_value 0.14 ;
                                 rdfs:label "IC025 for tocilizumab and psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisIC025ForTocilizumabAndPsoriasisAggravated
:IC025ForTocilizumabAndPsoriasisAggravated rdf:type owl:NamedIndividual ,
                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                           OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                                           OpenPVSignal:refers_to_drug :tocilizumab ;
                                           OpenPVSignal:refers_to_information_component :ICForTocilizumabAndPsoriasisAggravated ;
                                           OpenPVSignal:has_value 1.04 ;
                                           rdfs:label "IC025 for tocilizumab and psoriasis aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisICForTocilizumabAndPsoriasis
:ICForTocilizumabAndPsoriasis rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                              OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              OpenPVSignal:has_value 0.96 ;
                              rdfs:label "IC for tocilizumab and psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisICForTocilizumabAndPsoriasisAggravated
:ICForTocilizumabAndPsoriasisAggravated rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                        OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                                        OpenPVSignal:refers_to_drug :tocilizumab ;
                                        OpenPVSignal:has_value 2.21 ;
                                        rdfs:label "IC for tocilizumab and psoriasis aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisDosage1
:LiteraturePsoriasisDosage1 rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Dosage ;
                            OpenPVSignal:refers_to_drug :tocilizumab ;
                            OpenPVSignal:refers_to_interval_between_administrations :month_interval ;
                            OpenPVSignal:has_dosage_unit "mg/kg" ;
                            OpenPVSignal:has_value 8 ;
                            OpenPVSignal:refers_to_dose_value "8 mg/kg" ;
                            rdfs:label "Literature Psoriasis Dosage 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisDosage2
:LiteraturePsoriasisDosage2 rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Dosage ;
                            OpenPVSignal:refers_to_drug :tocilizumab ;
                            OpenPVSignal:refers_to_interval_between_administrations :month_interval ;
                            OpenPVSignal:has_dosage_unit "mg/kg" ;
                            OpenPVSignal:has_value 8 ;
                            OpenPVSignal:refers_to_dose_value "8 mg/kg" ;
                            rdfs:label "Literature Psoriasis Dosage 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisDosage3
:LiteraturePsoriasisDosage3 rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Dosage ;
                            OpenPVSignal:refers_to_drug :tocilizumab ;
                            OpenPVSignal:refers_to_interval_between_administrations :month_interval ;
                            OpenPVSignal:has_dosage_unit "mg/kg" ;
                            OpenPVSignal:has_value 8 ;
                            OpenPVSignal:refers_to_dose_value "8 mg/kg" ;
                            rdfs:label "Literature Psoriasis Dosage 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisDosage4
:LiteraturePsoriasisDosage4 rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Dosage ;
                            OpenPVSignal:refers_to_drug :tocilizumab ;
                            OpenPVSignal:refers_to_interval_between_administrations :month_interval ;
                            OpenPVSignal:has_dosage_unit "mg/kg" ;
                            OpenPVSignal:has_value 8 ;
                            OpenPVSignal:refers_to_dose_value "8 mg/kg" ;
                            rdfs:label "Literature Psoriasis Dosage 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisPatient1
:LiteraturePsoriasisPatient1 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:VigiBase_Report ;
                             OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                             OpenPVSignal:refers_to_concomitant_drug :prednisone ;
                             OpenPVSignal:refers_to_past_diagnosis :psoriasis ;
                             OpenPVSignal:refers_to_patient :Literature_psoriasis_Patient_1 ;
                             OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                             OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_literature_1 ;
                             OpenPVSignal:time_to_onset :LiteraturePsoriasisPatientTimeToOnset1 ;
                             OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                             OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
                             OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
                             rdfs:label "Report Literature 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisPatient2
:LiteraturePsoriasisPatient2 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:VigiBase_Report ;
                             OpenPVSignal:refers_to_adverse_effect :guttatePsoriasis ;
                             OpenPVSignal:refers_to_past_diagnosis :psoriasis ;
                             OpenPVSignal:refers_to_patient :Literature_psoriasis_Patient_2 ;
                             OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                             OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_literature_2 ;
                             OpenPVSignal:time_to_onset :LiteraturePsoriasisPatientTimeToOnset2 ;
                             OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                             OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
                             rdfs:label "Report Literature 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisPatient3
:LiteraturePsoriasisPatient3 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:VigiBase_Report ;
                             OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                             OpenPVSignal:refers_to_concomitant_drug :prednisone ;
                             OpenPVSignal:refers_to_patient :Literature_psoriasis_Patient_3 ;
                             OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                             OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_literature_3 ;
                             OpenPVSignal:time_to_onset :LiteraturePsoriasisPatientTimeToOnset3 ;
                             OpenPVSignal:refers_to_outcome_after_action "recovery without drug withdrawal" ;
                             rdfs:label "Report Literature 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisPatient4
:LiteraturePsoriasisPatient4 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:VigiBase_Report ;
                             OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                             OpenPVSignal:refers_to_concomitant_drug :methotrexate ,
                                                                     :prednisone ;
                             OpenPVSignal:refers_to_past_diagnosis :psoriasis ;
                             OpenPVSignal:refers_to_patient :Literature_psoriasis_Patient_4 ;
                             OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                             OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_literature_4 ;
                             rdfs:label "Report Literature 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisPatientTimeToOnset1
:LiteraturePsoriasisPatientTimeToOnset1 rdf:type owl:NamedIndividual ,
                                                 <http://www.w3.org/2006/time#DurationDescription> ;
                                        OpenPVSignal:has_content "10 days" ;
                                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                        <http://www.w3.org/2006/time#numericPosition> 10 ;
                                        rdfs:label "Literature psoriasis patient time to onset 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisPatientTimeToOnset2
:LiteraturePsoriasisPatientTimeToOnset2 rdf:type owl:NamedIndividual ,
                                                 <http://www.w3.org/2006/time#DurationDescription> ;
                                        OpenPVSignal:has_content "5 days" ;
                                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                        <http://www.w3.org/2006/time#numericPosition> 5 ;
                                        rdfs:label "Literature psoriasis patient time to onset 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiteraturePsoriasisPatientTimeToOnset3
:LiteraturePsoriasisPatientTimeToOnset3 rdf:type owl:NamedIndividual ,
                                                 <http://www.w3.org/2006/time#DurationDescription> ;
                                        OpenPVSignal:has_content "63 days" ;
                                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                        <http://www.w3.org/2006/time#numericPosition> 63 ;
                                        rdfs:label "Literature psoriasis patient time to onset 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiterature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Literature_information ;
                          mp:references :ref10 ,
                                        :ref11 ,
                                        :ref12 ;
                          OpenPVSignal:has_content "There are three published articles describing psoriasis or aggravated psoriasis occurring in four patients during tocilizumab use (Table 3).10-12 The indications were psoriatic and non-psoriatic. One young man also experienced a flare of pre-existing uveitis. The form of psoriasis was palmoplantar in one patient and guttate in another, in keeping with observations in the VigiBase ICSRs. Two patients recovered on dechallenge and one relapsed on rechallenge. However, this patient and one other tolerated further administrations while using topical psoriasis treatment. This suspected reaction does not appear in Martindale, Drugdex, the European Medicines Agency (EMA) Summary of Product Characteristics (SPC), or in the US Food and Drug Administration (FDA) label." ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiterature_psoriasis_Patient_1
:Literature_psoriasis_Patient_1 rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Patient ;
                                OpenPVSignal:has_age 37 ;
                                OpenPVSignal:has_gender "female" ;
                                rdfs:label "Literature psoriasis Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiterature_psoriasis_Patient_2
:Literature_psoriasis_Patient_2 rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Patient ;
                                OpenPVSignal:has_age 52 ;
                                OpenPVSignal:has_gender "female" ;
                                rdfs:label "Literature psoriasis Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiterature_psoriasis_Patient_3
:Literature_psoriasis_Patient_3 rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Patient ;
                                OpenPVSignal:has_age 55 ;
                                OpenPVSignal:has_gender "female" ;
                                rdfs:label "Literature psoriasis Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisLiterature_psoriasis_Patient_4
:Literature_psoriasis_Patient_4 rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Patient ;
                                OpenPVSignal:has_age 19 ;
                                OpenPVSignal:has_gender "male" ;
                                rdfs:label "Literature psoriasis Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisMechanism_of_Tocilizumab
:Mechanism_of_Tocilizumab rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Mechanism ;
                          mp:references :ref5 ;
                          OpenPVSignal:has_content "Tocilizumab is a humanised anti-human interleukin (IL)-6 receptor antibody. It competes for membrane- bound and soluble forms of human IL- 6 receptor, thereby inhibiting the binding of this native inflammatory cytokine to its receptor and interfering with the cytokine’s effects. This cytokine has the ability to activate T cells, B cells, macrophages and osteoclasts.  Increased synovial fluid IL-6 levels correlate with disease activity in rheumatoid arthritis (RA) and circulating levels are elevated in children with systemic juvenile idiopathic arthritis (JIA). Its approved indications include JIA and RA.5" ;
                          rdfs:label "Mechanism of Tocilizumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisProposed_mechanism_for_psoriasis_due_to_tocilizumab
:Proposed_mechanism_for_psoriasis_due_to_tocilizumab rdf:type owl:NamedIndividual ,
                                                              OpenPVSignal:Adverse_Effect_Mechanism ;
                                                     OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                                                     mp:references :ref10 ,
                                                                   :ref13 ;
                                                     OpenPVSignal:has_content "The mechanism whereby TNF inhibitors and tocilizumab might induce or aggravate psoriasis is unknown. Clearly this is a paradoxical reaction as these medicines inhibit the actions of pro- inflammatory cytokines. IL-6 appears to have a role in maintaining inflammation in psoriasis which includes promoting TNF and other cytokine production from T helper 17 cells which are important mediators in autoimmune diseases and host defence against extracellular pathogens.10 However, as there is evidence for abatacept and limited evidence for rituximab and anakinra causing psoriasis and these are biologic anti- rheumatic agents with various effects on the immune system,13 a specific mechanism related to TNF and IL-6 inhibition is less likely. Cytokine imbalance has been proposed as a possible mechanism.10" ;
                                                     rdfs:label "Proposed mechanism for psoriasis due to tocilizumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggPatientsTimeToOnset1
:PsoriasisAggPatientsTimeToOnset1 rdf:type owl:NamedIndividual ,
                                           <http://www.w3.org/2006/time#DurationDescription> ;
                                  OpenPVSignal:has_content "5 days" ;
                                  <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                  <http://www.w3.org/2006/time#numericPosition> 5 ;
                                  rdfs:label "Psoriasis agg patients time to onset 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggPatientsTimeToOnset2
:PsoriasisAggPatientsTimeToOnset2 rdf:type owl:NamedIndividual ,
                                           <http://www.w3.org/2006/time#DurationDescription> ;
                                  OpenPVSignal:has_content "55 days" ;
                                  <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                  <http://www.w3.org/2006/time#numericPosition> 55 ;
                                  rdfs:label "Psoriasis agg patients time to onset 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggPatientsTimeToOnset3
:PsoriasisAggPatientsTimeToOnset3 rdf:type owl:NamedIndividual ,
                                           <http://www.w3.org/2006/time#DurationDescription> ;
                                  OpenPVSignal:has_content "111 days" ;
                                  <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                  <http://www.w3.org/2006/time#numericPosition> 111 ;
                                  rdfs:label "Psoriasis agg patients time to onset 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggPatientsTimeToOnset4
:PsoriasisAggPatientsTimeToOnset4 rdf:type owl:NamedIndividual ,
                                           <http://www.w3.org/2006/time#DurationDescription> ;
                                  OpenPVSignal:has_content "191 days" ;
                                  <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                  <http://www.w3.org/2006/time#numericPosition> 191 ;
                                  rdfs:label "Psoriasis agg patients time to onset 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggPatientsTimeToOnset6
:PsoriasisAggPatientsTimeToOnset6 rdf:type owl:NamedIndividual ,
                                           <http://www.w3.org/2006/time#DurationDescription> ;
                                  OpenPVSignal:has_content "6 days" ;
                                  <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                  <http://www.w3.org/2006/time#numericPosition> 6 ;
                                  rdfs:label "Psoriasis agg patients time to onset 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggPatientsTimeToOnset7
:PsoriasisAggPatientsTimeToOnset7 rdf:type owl:NamedIndividual ,
                                           <http://www.w3.org/2006/time#DurationDescription> ;
                                  OpenPVSignal:has_content "143 days" ;
                                  <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                  <http://www.w3.org/2006/time#numericPosition> 143 ;
                                  rdfs:label "Psoriasis agg patients time to onset 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggravatedPatient1
:PsoriasisAggravatedPatient1 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Patient ;
                             OpenPVSignal:has_age 58 ;
                             OpenPVSignal:has_gender "female" ;
                             rdfs:label "Psoriasis aggravated Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggravatedPatient2
:PsoriasisAggravatedPatient2 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Patient ;
                             OpenPVSignal:has_age 49 ;
                             OpenPVSignal:has_gender "female" ;
                             rdfs:label "Psoriasis aggravated Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggravatedPatient3
:PsoriasisAggravatedPatient3 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Patient ;
                             OpenPVSignal:has_age 41 ;
                             OpenPVSignal:has_gender "female" ;
                             rdfs:label "Psoriasis aggravated Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggravatedPatient4
:PsoriasisAggravatedPatient4 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Patient ;
                             OpenPVSignal:has_age 56 ;
                             OpenPVSignal:has_gender "female" ;
                             rdfs:label "Psoriasis aggravated Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggravatedPatient5
:PsoriasisAggravatedPatient5 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Patient ;
                             OpenPVSignal:has_gender "female" ;
                             rdfs:label "Psoriasis aggravated Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggravatedPatient6
:PsoriasisAggravatedPatient6 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Patient ;
                             OpenPVSignal:has_age 51 ;
                             OpenPVSignal:has_gender "male" ;
                             rdfs:label "Psoriasis aggravated Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggravatedPatient7
:PsoriasisAggravatedPatient7 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Patient ;
                             OpenPVSignal:has_age 54 ;
                             OpenPVSignal:has_gender "female" ;
                             rdfs:label "Psoriasis aggravated Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisAggravatedPatient8
:PsoriasisAggravatedPatient8 rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Patient ;
                             OpenPVSignal:has_age 39 ;
                             OpenPVSignal:has_gender "female" ;
                             rdfs:label "Psoriasis aggravated Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient1
:PsoriasisPatient1 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   OpenPVSignal:has_gender "male" ;
                   rdfs:label "Psoriasis Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient10
:PsoriasisPatient10 rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Patient ;
                    OpenPVSignal:has_age 60 ;
                    OpenPVSignal:has_gender "female" ;
                    rdfs:label "Psoriasis Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient11
:PsoriasisPatient11 rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Patient ;
                    OpenPVSignal:has_gender "male" ;
                    rdfs:label "Psoriasis Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient12
:PsoriasisPatient12 rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Patient ;
                    OpenPVSignal:has_age 57 ;
                    OpenPVSignal:has_gender "female" ;
                    rdfs:label "Psoriasis Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient2
:PsoriasisPatient2 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   OpenPVSignal:has_gender "female" ;
                   rdfs:label "Psoriasis Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient3
:PsoriasisPatient3 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   OpenPVSignal:has_gender "female" ;
                   rdfs:label "Psoriasis Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient4
:PsoriasisPatient4 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   OpenPVSignal:has_gender "female" ;
                   rdfs:label "Psoriasis Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient5
:PsoriasisPatient5 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   OpenPVSignal:has_age 33 ;
                   OpenPVSignal:has_gender "female" ;
                   rdfs:label "Psoriasis Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient6
:PsoriasisPatient6 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   OpenPVSignal:has_gender "male" ;
                   rdfs:label "Psoriasis Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient7
:PsoriasisPatient7 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   OpenPVSignal:has_gender "female" ;
                   rdfs:label "Psoriasis Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient8
:PsoriasisPatient8 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   OpenPVSignal:has_gender "female" ;
                   rdfs:label "Psoriasis Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatient9
:PsoriasisPatient9 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Patient ;
                   rdfs:label "Psoriasis Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsDosage10
:PsoriasisPatientsDosage10 rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Dosage ;
                           OpenPVSignal:refers_to_drug :tocilizumab ;
                           OpenPVSignal:refers_to_interval_between_administrations :week_interval ;
                           OpenPVSignal:has_dosage_unit "mg" ;
                           OpenPVSignal:has_value 650 ;
                           OpenPVSignal:refers_to_dose_value "650 mg" ;
                           rdfs:label "Psoriasis Patients Dosage 10" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsDosage12
:PsoriasisPatientsDosage12 rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Dosage ;
                           OpenPVSignal:refers_to_drug :tocilizumab ;
                           OpenPVSignal:has_dosage_unit "mg" ;
                           OpenPVSignal:has_value 400 ;
                           OpenPVSignal:refers_to_dose_value "400 mg" ;
                           rdfs:label "Psoriasis Patients Dosage 12" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsDosage2
:PsoriasisPatientsDosage2 rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Dosage ;
                          OpenPVSignal:refers_to_drug :tocilizumab ;
                          OpenPVSignal:has_dosage_unit "mg" ;
                          OpenPVSignal:has_value 400 ;
                          OpenPVSignal:refers_to_dose_value "400 mg" ;
                          rdfs:label "Psoriasis Patients Dosage 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsDosage3
:PsoriasisPatientsDosage3 rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Dosage ;
                          OpenPVSignal:refers_to_drug :tocilizumab ;
                          OpenPVSignal:refers_to_interval_between_administrations :week_interval ;
                          OpenPVSignal:has_dosage_unit "mg" ;
                          OpenPVSignal:has_value 280 ;
                          OpenPVSignal:refers_to_dose_value "280 mg" ;
                          rdfs:label "Psoriasis Patients Dosage 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsDosage5
:PsoriasisPatientsDosage5 rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Dosage ;
                          OpenPVSignal:refers_to_drug :tocilizumab ;
                          OpenPVSignal:refers_to_interval_between_administrations :week_interval ;
                          OpenPVSignal:has_dosage_unit "mg/kg" ;
                          OpenPVSignal:has_value 8 ;
                          OpenPVSignal:refers_to_dose_value "8 mg/kg" ;
                          rdfs:label "Psoriasis Patients Dosage 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsDosage6
:PsoriasisPatientsDosage6 rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Dosage ;
                          OpenPVSignal:refers_to_drug :tocilizumab ;
                          OpenPVSignal:refers_to_interval_between_administrations :month_interval ;
                          OpenPVSignal:has_dosage_unit "mg/kg" ;
                          OpenPVSignal:has_value 8 ;
                          OpenPVSignal:refers_to_dose_value "8 mg/kg" ;
                          rdfs:label "Psoriasis Patients Dosage 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsDosage7
:PsoriasisPatientsDosage7 rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Dosage ;
                          OpenPVSignal:refers_to_drug :tocilizumab ;
                          OpenPVSignal:has_dosage_unit "mg/kg" ;
                          OpenPVSignal:has_value 8 ;
                          OpenPVSignal:refers_to_dose_value "8 mg/kg" ;
                          rdfs:label "Psoriasis Patients Dosage 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsDosage8
:PsoriasisPatientsDosage8 rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Dosage ;
                          OpenPVSignal:refers_to_drug :tocilizumab ;
                          OpenPVSignal:refers_to_interval_between_administrations :month_interval ;
                          OpenPVSignal:has_dosage_unit "mg" ;
                          OpenPVSignal:has_value 360 ;
                          OpenPVSignal:refers_to_dose_value "360 mg" ;
                          rdfs:label "Psoriasis Patients Dosage 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsTimeToOnset12
:PsoriasisPatientsTimeToOnset12 rdf:type owl:NamedIndividual ,
                                         <http://www.w3.org/2006/time#DurationDescription> ;
                                OpenPVSignal:has_content "21 days" ;
                                <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                <http://www.w3.org/2006/time#numericPosition> 21 ;
                                rdfs:label "Psoriasis patients time to onset 12" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsTimeToOnset3
:PsoriasisPatientsTimeToOnset3 rdf:type owl:NamedIndividual ,
                                        <http://www.w3.org/2006/time#DurationDescription> ;
                               OpenPVSignal:has_content "One day" ;
                               <http://www.w3.org/2006/time#nominalPosition> "days" ;
                               <http://www.w3.org/2006/time#numericPosition> 1 ;
                               rdfs:label "Psoriasis patients time to onset 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsTimeToOnset5
:PsoriasisPatientsTimeToOnset5 rdf:type owl:NamedIndividual ,
                                        <http://www.w3.org/2006/time#DurationDescription> ;
                               OpenPVSignal:has_content "17 days" ;
                               <http://www.w3.org/2006/time#nominalPosition> "days" ;
                               <http://www.w3.org/2006/time#numericPosition> 17 ;
                               rdfs:label "Psoriasis patients time to onset 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisPsoriasisPatientsTimeToOnset8
:PsoriasisPatientsTimeToOnset8 rdf:type owl:NamedIndividual ,
                                        <http://www.w3.org/2006/time#DurationDescription> ;
                               OpenPVSignal:has_content "85 days Three doses, one each month over" ;
                               <http://www.w3.org/2006/time#nominalPosition> "days" ;
                               <http://www.w3.org/2006/time#numericPosition> 85 ;
                               rdfs:label "Psoriasis patients time to onset 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportAgg.Psoriasis1
:ReportAgg.Psoriasis1 rdf:type owl:NamedIndividual ,
                               OpenPVSignal:VigiBase_Report ;
                      OpenPVSignal:refers_to_adverse_effect :Rheumatoid_arthritis_aggravated ,
                                                            :psoriasisAggravated ,
                                                            :sweating ;
                      OpenPVSignal:refers_to_concomitant_drug :duloxetine ,
                                                              :pantoprazole ,
                                                              :thyroxine ,
                                                              <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#hydrochlorothiazide_/_valsartan> ;
                      OpenPVSignal:refers_to_patient :PsoriasisAggravatedPatient1 ;
                      OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                      OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_agg_psoriasis_1 ;
                      OpenPVSignal:time_to_onset :PsoriasisAggPatientsTimeToOnset1 ;
                      OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                      rdfs:label "Report Agg. Psoriasis 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportAgg.Psoriasis2
:ReportAgg.Psoriasis2 rdf:type owl:NamedIndividual ,
                               OpenPVSignal:VigiBase_Report ;
                      OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                      OpenPVSignal:refers_to_concomitant_drug :methotrexate ;
                      OpenPVSignal:refers_to_patient :PsoriasisAggravatedPatient2 ;
                      OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                      OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_agg_psoriasis_2 ;
                      OpenPVSignal:time_to_onset :PsoriasisAggPatientsTimeToOnset2 ;
                      OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                      rdfs:label "Report Agg. Psoriasis 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportAgg.Psoriasis3
:ReportAgg.Psoriasis3 rdf:type owl:NamedIndividual ,
                               OpenPVSignal:VigiBase_Report ;
                      OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                      OpenPVSignal:refers_to_concomitant_drug :methotrexate ;
                      OpenPVSignal:refers_to_patient :PsoriasisAggravatedPatient3 ;
                      OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                      OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_agg_psoriasis_3 ;
                      OpenPVSignal:time_to_onset :PsoriasisAggPatientsTimeToOnset3 ;
                      OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                      rdfs:label "Report Agg. Psoriasis 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportAgg.Psoriasis4
:ReportAgg.Psoriasis4 rdf:type owl:NamedIndividual ,
                               OpenPVSignal:VigiBase_Report ;
                      OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                      OpenPVSignal:refers_to_concomitant_drug :fenofibrate ,
                                                              :methylprednisolone ,
                                                              :telmisartan ,
                                                              :thyroxine ,
                                                              :ticlopidine ;
                      OpenPVSignal:refers_to_patient :PsoriasisAggravatedPatient4 ;
                      OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                      OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_agg_psoriasis_4 ;
                      OpenPVSignal:time_to_onset :PsoriasisAggPatientsTimeToOnset4 ;
                      OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                      rdfs:label "Report Agg. Psoriasis 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportAgg.Psoriasis5
:ReportAgg.Psoriasis5 rdf:type owl:NamedIndividual ,
                               OpenPVSignal:VigiBase_Report ;
                      OpenPVSignal:refers_to_adverse_effect :anaemia ,
                                                            :psoriasisAggravated ;
                      OpenPVSignal:refers_to_patient :PsoriasisAggravatedPatient5 ;
                      OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                      OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_agg_psoriasis_5 ;
                      OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                      rdfs:label "Report Agg. Psoriasis 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportAgg.Psoriasis6
:ReportAgg.Psoriasis6 rdf:type owl:NamedIndividual ,
                               OpenPVSignal:VigiBase_Report ;
                      OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                      OpenPVSignal:refers_to_patient :PsoriasisAggravatedPatient6 ;
                      OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                      OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_agg_psoriasis_6 ;
                      OpenPVSignal:time_to_onset :PsoriasisAggPatientsTimeToOnset6 ;
                      OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                      rdfs:label "Report Agg. Psoriasis 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportAgg.Psoriasis7
:ReportAgg.Psoriasis7 rdf:type owl:NamedIndividual ,
                               OpenPVSignal:VigiBase_Report ;
                      OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                      OpenPVSignal:refers_to_concomitant_drug :celecoxib ,
                                                              :codeineAndParacetamol ,
                                                              :colecalciferol ;
                      OpenPVSignal:refers_to_patient :PsoriasisAggravatedPatient7 ;
                      OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                      OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_agg_psoriasis_7 ;
                      OpenPVSignal:time_to_onset :PsoriasisAggPatientsTimeToOnset7 ;
                      OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                      rdfs:label "Report Agg. Psoriasis 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportAgg.Psoriasis8
:ReportAgg.Psoriasis8 rdf:type owl:NamedIndividual ,
                               OpenPVSignal:VigiBase_Report ;
                      OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                      OpenPVSignal:refers_to_patient :PsoriasisAggravatedPatient8 ;
                      OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                      OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_agg_psoriasis_8 ;
                      OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                      rdfs:label "Report Agg. Psoriasis 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis1
:ReportPsoriasis1 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient1 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_1 ;
                  OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                  rdfs:label "Report Psoriasis 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis10
:ReportPsoriasis10 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:VigiBase_Report ;
                   OpenPVSignal:refers_to_adverse_effect :conjunctivitis ,
                                                         :cyst ,
                                                         :folliculitis ,
                                                         :psoriasis ;
                   OpenPVSignal:refers_to_concomitant_drug :folicAcid ,
                                                           :hydroxyzine ,
                                                           :metronidazole ,
                                                           :sulphasalazine ;
                   OpenPVSignal:refers_to_patient :PsoriasisPatient10 ;
                   OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                   OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_10 ;
                   OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                   rdfs:label "Report Psoriasis 10" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis11
:ReportPsoriasis11 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:VigiBase_Report ;
                   OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                   OpenPVSignal:refers_to_concomitant_drug :methotrexate ;
                   OpenPVSignal:refers_to_patient :PsoriasisPatient11 ;
                   OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                   OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                   rdfs:label "Report Psoriasis 11" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis12
:ReportPsoriasis12 rdf:type owl:NamedIndividual ,
                            OpenPVSignal:VigiBase_Report ;
                   OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                   OpenPVSignal:refers_to_concomitant_drug :methylprednisolone ,
                                                           :telmisartan ,
                                                           :thyroxine ,
                                                           :ticlopidine ;
                   OpenPVSignal:refers_to_patient :PsoriasisPatient12 ;
                   OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                   OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_12 ;
                   OpenPVSignal:time_to_onset :PsoriasisPatientsTimeToOnset12 ;
                   OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                   rdfs:label "Report Psoriasis 12" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis2
:ReportPsoriasis2 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :pustularPsoriasis ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient2 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_2 ;
                  OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                  rdfs:label "Report Psoriasis 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis3
:ReportPsoriasis3 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :pustularPsoriasis ;
                  OpenPVSignal:refers_to_concomitant_drug :methotrexate ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient3 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_3 ;
                  OpenPVSignal:time_to_onset :PsoriasisPatientsTimeToOnset3 ;
                  OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                  OpenPVSignal:refers_to_outcome_after_action "recovering" ;
                  rdfs:label "Report Psoriasis 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis4
:ReportPsoriasis4 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient4 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_dechallenge_outcome "unknown" ;
                  OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                  rdfs:label "Report Psoriasis 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis5
:ReportPsoriasis5 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                  OpenPVSignal:refers_to_concomitant_drug :paracetamol ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient5 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_5 ;
                  OpenPVSignal:time_to_onset :PsoriasisPatientsTimeToOnset5 ;
                  OpenPVSignal:refers_to_outcome_after_action "recovering" ;
                  rdfs:label "Report Psoriasis 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis6
:ReportPsoriasis6 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                  OpenPVSignal:refers_to_concomitant_drug :diclofenac ,
                                                          :prednisone ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient6 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_6 ;
                  OpenPVSignal:refers_to_outcome_after_action "recovering" ;
                  rdfs:label "Report Psoriasis 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis7
:ReportPsoriasis7 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                  OpenPVSignal:refers_to_concomitant_drug :prednisone ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient7 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_7 ;
                  OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                  rdfs:label "Report Psoriasis 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis8
:ReportPsoriasis8 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :pustularPsoriasis ;
                  OpenPVSignal:refers_to_concomitant_drug :loxoprofen ,
                                                          :methotrexate ,
                                                          :rebamipide ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient8 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_8 ;
                  OpenPVSignal:time_to_onset :PsoriasisPatientsTimeToOnset8 ;
                  OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                  rdfs:label "Report Psoriasis 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportPsoriasis9
:ReportPsoriasis9 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:VigiBase_Report ;
                  OpenPVSignal:refers_to_adverse_effect :Bullous_pemphigoid ,
                                                        :psoriasis ;
                  OpenPVSignal:refers_to_patient :PsoriasisPatient9 ;
                  OpenPVSignal:refers_to_primary_suspect_drug :tocilizumab ;
                  OpenPVSignal:refers_to_reported_drug_usage :usage_for_report_psoriasis_9 ;
                  OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                  rdfs:label "Report Psoriasis 9" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReportsInVigibaseForPsoriasisAndTocilizumab
:ReportsInVigibaseForPsoriasisAndTocilizumab rdf:type owl:NamedIndividual ,
                                                      OpenPVSignal:Reports_group ;
                                             OpenPVSignal:is_subgroup_of <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reportsInVigibaseForPsoriasis&PsoriasisAggravated> ;
                                             OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                                             OpenPVSignal:refers_to_drug :tocilizumab ;
                                             OpenPVSignal:has_count 12 ;
                                             OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                             rdfs:label "Reports in vigibase for psoriasis and tocilizumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisReports_in_VigiBase
:Reports_in_VigiBase rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Free_text_reporting_element ;
                     mp:references :ref2 ,
                                   :ref8 ,
                                   :ref9 ;
                     OpenPVSignal:has_content """In the second quarter of 2013, after removal of three duplicates, there were 12 ICSRs for psoriasis (Table 1) and eight for aggravated psoriasis (Table
2) associated with tocilizumab use. The reports were from nine countries, the United States, the United Kingdom, Italy, Belgium, Canada, Spain, Australia, Switzerland and Sweden. The combination tocilizumab/psoriasis aggravated became statistically prominent in the second quarter of 2011 (IC 2.21, IC025 1.04) and tocilizumab/psoriasis in the first quarter of 2013 (IC 0.96, IC025 0.14) when the total number of reports in VigiBase® for tocilizumab was 3,796. The gender distribution was 15 females and four males in the combined ICSRs for the psoriasis and aggravated psoriasis combinations. In one case gender was not specified. Since the most frequent indication for tocilizumab was RA this observation of female preponderance is not unexpected. Age was documented in only three of the 12 ICSRs for psoriasis but was recorded for seven of the eight patients with aggravated psoriasis. The range for the combined psoriasis and aggravated psoriasis reports was 33 to 60 years and, for aggravated psoriasis, 39 to 58 years with a median of 51 years.
As well as RA, other indications for tocilizumab were psoriatic arthropathy (two cases) and seronegative rheumatoid arthritis (one case) in the aggravated psoriasis group and juvenile arthritis (one case) in the psoriasis group. While none of the patients in the psoriasis group had a reported history of psoriasis, psoriatic arthritis may present as arthritis before psoriasis develops so the patient with juvenile arthritis may have been redisposed.2
The recommended dose and dose frequency of tocilizumab is 8 mg/kg monthly for adults with RA and 8 mg/kg two weekly for children weighing more than 30 kg with systemic JIA. Exceeding a dose of 800 mg is not recommended.8
The reports indicate that, where recorded, the doses tended to be higher for the aggravated psoriasis group compared with the psoriasis group, although only one patient in the former group received greater than the recommended dose (880 mg). However, two patients whose dose intervals were shorter than recommended (weekly) were in the psoriasis group.
The duration of tocilizumab use to onset of psoriasis was 1 to 85 days, median 19 days, for the psoriasis group (four patients) and 5 to 191 days, median 84 days, for the aggravated psoriasis group (six patients).
One patient had experienced a similar reaction to rituximab, a biologic B-cell depleting agent whose indications include autoimmune disorders, with recurrence on rechallenge. TNF inhibitors had been ineffective in this patient and had not caused psoriasis (Table 2, ICSR1). There was no record of previous exposure to bio- logic antirheumatic medicines in the other reports. Five patients were taking methotrexate and one sulphasalazine, both of which are disease-modifying anti-rheumatic drugs (DMARDs). However, psoriasis is not a recognized reaction to non-biologic DMARDs and one study found no evidence that non-biologic DMARDs caused or aggravated psoriasis in a cohort of 2,880 patients.9 There was no consistent use of other medicines, suggesting an alternative explanation for psoriasis or an interaction with tocilizumab. However, some ICSRs were not well-documented and information on concomitant medicines or previous exposures may have been omitted.
The psoriasis was described as guttate in two ICSRs of aggravated psoriasis and pustular in three ICSRs of psoriasis. One patient with psoriasis had a bullous psoriatic reaction affecting the plantar area which was described as “impressive” and occurred several times, always after a tocilizumab infusion, (Table 1, ICSR 9).
Two ICSRs indicated serious reactions. One patient with guttate psoriasis required hospital admission and one patient’s pustular psoriasis was assessed as disabling or incapacitating.
Of the 12 ICSRs for psoriasis, one patient with pustular psoriasis was recovering after tocilizumab was dis- continued, (Table 1, ICSR 3), and one patient, descri- bed above, developed episodes of psoriasis, described as bullous and plantar, which always occurred after a tocilizumab infusion, (Table 1, ICSR 9). Three other patients recovered or were recovering but the date of stopping tocilizumab in relation to recovery was unclear or not documented.
Of the eight ICSRs for aggravated psoriasis, one patient developed a massive increase in guttate psoriasis and seronegative rheumatoid arthritis five days after one dose of tocilizumab, (Table 2, ICSR 1). This is the patient who had reacted similarly five months previously to rituximab with recurrence on rechallenge. Three patients with aggravated psoriasis had not recovered at the time of reporting and the outcome was unknown for the remaining four.""" ;
                     rdfs:label "Reports in VigiBase" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisResponse_from_Roche
:Response_from_Roche rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Response_to_Pharmacovigilance_Signal_Report ;
                     OpenPVSignal:has_content "The Uppsala Monitoring Centre (UMC) of the WHO Collaborating Centre for International Drug Monitoring, identified psoriasis as a technical signal in their Global ICSR database Vigibase® based on calculated Information Component (IC) values. 12 ICSRs for psoriasis and 8 ICSRs for aggravated psoriasis were identified in the second quarter of 2013, after removal of three duplicates. “The combination tocilizumab/ psoriasis aggravated became statistically prominent in the second quarter of 2011(IC 2.21, IC025 1.04) and tocilizumab/psoriasis in the first quarter of 2013 (IC 0.96, IC025 0.14) when the total number of reports in Vigibase® for tocilizumab was 3,796.” Roche has been invited to comment on this technical signal relating to tocilizumab and psoriasis. The safety of patients is of the utmost importance to Roche, and adverse event reports from patients and physicians taking our medicinal products in clinical trials and in the post-marketing setting are continuously monitored and assessed. These events are reported to regulatory authorities in accordance with the respective regulations and safety guidelines. Roche uses the MedDRA coding dictionary for its Global Drug Safety Database ARISg, which includes spontaneous reports from the post-marketing setting and serious adverse events and non-serious adverse events of special interest from clinical trials. In MedDRA, the High-Level Term (HLT): psoriatic conditions and the HLT: psoriatic arthropathies was used to identify potential cases of psoriasis and then a cumulative review (through 10 April 2013) of these potential psoriasis events was performed. This cumulative review showed that a majority of reported cases contained minimal information precluding definitive causality assessment. About 20 % of reported cases had a preexisting history of psoriasis and an additional ~15% cases were reported with his- tory of anti-TNF use. As stated in the article above, the vast majority of published cases of biologic DMARD- associated psoriasis have occurred with the TNF inhibitors. The four cases of psoriasis cited in the literature, that describe evidence on positive re-challenge or positive de-challenge are described as follows: two of the 4 cases had history of anti-TNF use. One case discontinued tocilizumab treatment with resolution of psoriasis symptoms; however, the patient’s RA symptoms recurred. She opted to go back to tocilizumab treatment and manage her psoriasis symptoms with topical steroids instead. The last case of psoriasis had prior history of cutaneous eruptions. The patient developed exacerbation of the lesion after the 3rd tocilizumab dose. The status of psoriasis as well as the tocilizumab treatment was not provided. These cases are included in the cumulative review completed by Roche described above. Of note, in the published literature, there are also case reports describing the successful use of tocilizumab in patients with psoriatic arthritis1 or anti-TNF induced palmoplantar pustulosis, which is a type of psoriasiform lesion2 . In conclusion, there does not appear to be a causal relationship between psoriasis and tocilizumab. Roche will continue to monitor this condition. No updates to the product information documents and no changes to the conduct of clinical trials are warranted at this point in time. Roche will continue to monitor and obtain as much information as possible on received reports. The benefit/risk assessment of tocilizumab remains unchanged. References: 1. Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford). 2013 Sep;52(9):1728-9. 2. Rueda-Gotor J, González-Gay MA, Blanco Alonso R. Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis. Joint Bone Spine. 2012 Oct;79(5):510-3." ;
                     rdfs:label "Response from Roche" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisRheumatoid_arthritis_aggravated
:Rheumatoid_arthritis_aggravated rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Adverse_Effect ;
                                 OpenPVSignal:has_MedDRA_code 10039074 ;
                                 OpenPVSignal:has_MedDRA_prefered_term "Rheumatoid arthritis aggravated" ;
                                 rdfs:label "rheumatoid arthritis aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisTNF_inhibitors_and_psoriasis
:TNF_inhibitors_and_psoriasis rdf:type owl:NamedIndividual ,
                                       obo:OAE_0001197 ,
                                       OpenPVSignal:Structured_Product_Labels_information ,
                                       OpenPVSignal:Warning_Information ;
                              OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                              OpenPVSignal:refers_to_class :tnfInhibitors ;
                              OpenPVSignal:refers_to_drug :abatacept ;
                              mp:references :ref6 ,
                                            :ref7 ;
                              OpenPVSignal:has_content "In their respective summaries of product characteristics (SPCs), psoriasis is recognised as a possible adverse effect of tumour necrosis factor (TNF) inhibitors and abatacept, a costimulation blocking soluble fusion protein.6,7 Like tocilizumab, both are biologic disease-modifying anti-rheumatic agents." ;
                              rdfs:label "TNF inhibitors and abatacept and psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisTocilizumab-Psoriasis_and_aggravated_psoriasis
:Tocilizumab-Psoriasis_and_aggravated_psoriasis rdf:type owl:NamedIndividual ,
                                                         OpenPVSignal:Pharmacovigilance_Signal_Report ;
                                                OpenPVSignal:refers_to_author :Dr_Ruth_Savage ;
                                                OpenPVSignal:refers_to_signal :pvSingal ;
                                                OpenPVSignal:has_creation_date "01/05/2014" ;
                                                OpenPVSignal:has_overall_conclusion "causal association probable" ;
                                                rdfs:label "Tocilizumab-Psoriasis and aggravated psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisTocilizumab_usage
:Tocilizumab_usage rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Drug_Usage ;
                   OpenPVSignal:concerns_indication_for_use :juvenileIdiopathicArthritis ,
                                                            :rheumatoidArthritis ;
                   OpenPVSignal:refers_to_dosage :recommended_dosage ;
                   OpenPVSignal:refers_to_drug :tocilizumab ;
                   rdfs:label "Tocilizumab usage" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisabatacept
:abatacept rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_mechanism :Proposed_mechanism_for_psoriasis_due_to_tocilizumab ;
           OpenPVSignal:has_ATC_code "L04AA24" ;
           rdfs:label "abatacept" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisanaemia
:anaemia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10002034 ;
         OpenPVSignal:has_MedDRA_prefered_term "Anaemia" ;
         rdfs:label "anaemia" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisanakinra
:anakinra rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_mechanism :Proposed_mechanism_for_psoriasis_due_to_tocilizumab ;
          OpenPVSignal:has_ATC_code "L04AC03" ;
          rdfs:label "anakinra" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisankylosingSpondylitis
:ankylosingSpondylitis rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Indication ;
                       OpenPVSignal:has_ICD_code "M459" ;
                       OpenPVSignal:has_MedDRA_code 10002556 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Ankylosing spondylitis" ;
                       rdfs:label "ankylosing spondylitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasiscelecoxib
:celecoxib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "G01AE10" ,
                                     "L01XX33" ,
                                     "M01AH01" ;
           rdfs:label "celecoxib" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasiscodeineAndParacetamol
:codeineAndParacetamol rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Drug ;
                       OpenPVSignal:has_ATC_code "N02AJ06" ;
                       rdfs:label "codeine and paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasiscolecalciferol
:colecalciferol rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "A11CC05" ;
                rdfs:label "colecalciferol" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisconjunctivitis
:conjunctivitis rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10010741 ;
                OpenPVSignal:has_MedDRA_prefered_term "Conjunctivitis" ;
                rdfs:label "conjunctivitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasiscyst
:cyst rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_MedDRA_code 10011732 ;
      OpenPVSignal:has_MedDRA_prefered_term "Cyst" ;
      rdfs:label "cyst" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisdiclofenac
:diclofenac rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "D11AX18" ,
                                      "M01AB05" ,
                                      "M01AB55" ,
                                      "M02AA15" ,
                                      "S01BC03" ,
                                      "S01CC01" ;
            rdfs:label "diclofenac" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisduloxetine
:duloxetine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06AX21" ;
            rdfs:label "duloxetine" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisfenofibrate
:fenofibrate rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "C10AB05" ,
                                       "C10BA03" ,
                                       "C10BA04" ;
             rdfs:label "fenofibrate" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisfolicAcid
:folicAcid rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "B03AE01" ,
                                     "B03AE02" ,
                                     "B03BB01" ,
                                     "B03BB51" ;
           rdfs:label "folic acid" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisfolliculitis
:folliculitis rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10016936 ;
              OpenPVSignal:has_MedDRA_prefered_term "Folliculitis" ;
              rdfs:label "folliculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisguttatePsoriasis
:guttatePsoriasis rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "L404" ;
                  OpenPVSignal:has_MedDRA_code 10018797 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Guttate psoriasis" ;
                  rdfs:label "guttate psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasishydroxyzine
:hydroxyzine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N05BB01" ,
                                       "N05BB51" ;
             rdfs:label "hydroxyzine" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisincidenceOfInflammatoryArthropathyInPsoriasisPatients
:incidenceOfInflammatoryArthropathyInPsoriasisPatients rdf:type owl:NamedIndividual ,
                                                                OpenPVSignal:Incidence ;
                                                       OpenPVSignal:refers_to_adverse_effect :psoriasis ,
                                                                                             :psoriaticArthropathy ;
                                                       OpenPVSignal:has_value 0.05 ;
                                                       rdfs:label "incidence of inflammatory arthropathy in psoriasis patients" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisincidence_of_psoriasis
:incidence_of_psoriasis rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Incidence ;
                        OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                        OpenPVSignal:has_value 0.02 ;
                        rdfs:label "incidence of psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisintroduction
:introduction rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Introduction ;
              mp:references :ref1 ,
                            :ref2 ,
                            :ref3 ,
                            :ref4 ,
                            :ref5 ,
                            :ref6 ,
                            :ref7 ;
              OpenPVSignal:has_content """Psoriasis is an autoimmune inflammatory disease that usually presents with the development of inflammatory plaques on the skin. Studies have shown that it is likely that interactions between dendritic cells, T cells, keratinocytes, neutrophils and the cytokines released from immune cells contribute to the initiation and perpetuation of the cutaneous inflammation characteristic of psoriasis.1 Psoriasis affects about 2% of the population. In about 80% of patients psoriasis occurs as chronic plaque lesions. Palmoplantar variants include plaque psoriasis confined to the palms and soles, and pustular lesions on these surfaces (palmoplantar pustulosis). Rarely, an unrelated generalised and life-threatening pustulosis may develop. Another variant is guttate psoriasis which presents as a rash of drop-like lesions, often after a beta-haemolytic streptococcal infection. About 5% of patients with psoriasis develop an inflammatory arthropathy.2-4
Tocilizumab is a humanised anti-human interleukin (IL)-6 receptor antibody. It competes for membrane- bound and soluble forms of human IL- 6 receptor, thereby inhibiting the binding of this native inflammatory cytokine to its receptor and interfering with the cytokine’s effects. This cytokine has the ability to activate T cells, B cells, macrophages and osteoclasts. Increased synovial fluid IL-6 levels correlate with disease activity in rheumatoid arthritis (RA) and circulating levels are elevated in children with systemic juvenile idiopathic arthritis (JIA). Its approved indications include JIA and RA.5
In their respective summaries of product characteristics (SPCs), psoriasis is recognised as a possible adverse effect of tumour necrosis factor (TNF) inhibitors and abatacept, a costimulation blocking soluble fusion protein.6,7 Like tocilizumab, both are biologic disease-modifying anti-rheumatic agents.""" ;
              rdfs:label "introduction" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisjuvenileArthritis
:juvenileArthritis rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Indication ;
                   OpenPVSignal:has_ICD_code "M0809" ;
                   OpenPVSignal:has_MedDRA_code 10059176 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Juvenile idiopathic arthritis" ;
                   rdfs:label "juvenile arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisjuvenileIdiopathicArthritis
:juvenileIdiopathicArthritis rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Indication ;
                             OpenPVSignal:has_ICD_code "M0809" ;
                             OpenPVSignal:has_MedDRA_code 10059176 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Juvenile idiopathic arthritis" ;
                             rdfs:label "juvenile idiopathic arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisloxoprofen
:loxoprofen rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "M02AA31" ;
            rdfs:label "loxoprofen" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasismethotrexate
:methotrexate rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "L01BA01" ,
                                        "L04AX03" ;
              rdfs:label "methotrexate" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasismethylprednisolone
:methylprednisolone rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug ;
                    OpenPVSignal:has_ATC_code "D07AA01" ,
                                              "D07AC14" ,
                                              "D07CA02" ,
                                              "D10AA02" ,
                                              "H02AB04" ,
                                              "H02BX01" ,
                                              "S01CA08" ;
                    rdfs:label "methylprednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasismetronidazole
:metronidazole rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "A01AB17" ,
                                         "A02BD01" ,
                                         "A02BD02" ,
                                         "A02BD03" ,
                                         "A02BD08" ,
                                         "A02BD11" ,
                                         "D06BX01" ,
                                         "G01AF01" ,
                                         "G01AF20" ,
                                         "J01RA03" ,
                                         "J01RA04" ,
                                         "J01RA10" ,
                                         "J01XD01" ,
                                         "P01AB01" ,
                                         "P01AB51" ;
               rdfs:label "metronidazole" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasismonth_interval
:month_interval rdf:type owl:NamedIndividual ,
                         <http://www.w3.org/2006/time#DurationDescription> ;
                <http://www.w3.org/2006/time#nominalPosition> "months" ;
                <http://www.w3.org/2006/time#numericPosition> 1 ;
                rdfs:label "month interval" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispantoprazole
:pantoprazole rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A02BC02" ,
                                        "A02BD04" ,
                                        "A02BD11" ;
              rdfs:label "pantoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisparacetamol
:paracetamol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N02BE01" ;
             rdfs:label "paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisprednisone
:prednisone rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A07EA03" ,
                                      "H02AB07" ;
            rdfs:label "prednisone" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispsoriasis
:psoriasis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ,
                    OpenPVSignal:Past_Diagnosis ;
           OpenPVSignal:has_ICD_code "L40" ;
           OpenPVSignal:has_MedDRA_code 10037153 ;
           OpenPVSignal:has_MedDRA_prefered_term "Psoriasis" ;
           rdfs:label "psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispsoriasisAggravated
:psoriasisAggravated rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "L40" ;
                     OpenPVSignal:has_MedDRA_code 10037154 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Psoriasis aggravated" ;
                     rdfs:label "psoriasis aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispsoriasis_associated_with_antirhematoid_agents
:psoriasis_associated_with_antirhematoid_agents rdf:type owl:NamedIndividual ,
                                                         obo:OAE_0001197 ;
                                                mp:references :ref6 ,
                                                              :ref9 ;
                                                OpenPVSignal:has_content "The morphology of psoriasis occurring in association with biologic anti-rheumatic agent use is also of interest. The vast majority of published cases of biologic DMARD-associated psoriasis have occurred with the TNF inhibitors. Analyses of case reports in the US FDA adverse events reporting system (AERS) database and the British Society for Rheumatology Biologics Register (BSRBR) have provided information about the characteristics of these reports.6,9 In the FDA series of reports of patients taking a TNF inhibitor for non-psoriatic indications about 17% of patients developed palmoplantar and 15% pustular psoriasis. Palmoplantar pustular psoriasis predominated in the BSRBR reports, and guttate psoriasis was also reported. When the VigiBase ICSRs are combined with the published tocilizumab reports, 8 of the 24 ICSRs (33%) describe pustular, palmoplantar or guttate psoriasis. Assuming that the remainder of the patients developed generalised plaque psoriasis (as the nature of their psoriasis was not described), the proportion of patients with other types of lesions with tocilizumab is greater than the 20% expected for psoriasis in general, although a larger case series would be needed to confirm this." ;
                                                rdfs:label "psoriasis associated with antirhematoid agents" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispsoriasis_pathophysiology
:psoriasis_pathophysiology rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Free_text_reporting_element ;
                           OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                           mp:references :ref1 ,
                                         :ref2 ,
                                         :ref3 ,
                                         :ref4 ;
                           OpenPVSignal:has_content "Psoriasis is an autoimmune inflammatory disease that usually presents with the development of inflammatory plaques on the skin. Studies have shown that it is likely that interactions between dendritic cells, T cells, keratinocytes, neutrophils and the cytokines released from immune cells contribute to the initiation and perpetuation of the cutaneous inflammation characteristic of psoriasis. 1 Psoriasis affects about 2% of the population. In about 80% of patients psoriasis occurs as chronic plaque lesions. Palmoplantar variants include plaque psoriasis confined to the palms and soles, and pustular lesions on these surfaces (palmoplantar pustulosis). Rarely, an unrelated generalised and life-threatening pustulosis may develop. Another variant is guttate psoriasis which presents as a rash of drop-like lesions, often after a beta-haemolytic streptococcal infection. About 5% of patients with psoriasis develop an inflammatory arthropathy.2-4" ;
                           rdfs:label "psoriasis pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispsoriaticArthritis
:psoriaticArthritis rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Indication ;
                    OpenPVSignal:has_ICD_code "L4052" ;
                    OpenPVSignal:has_MedDRA_code 10037160 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Psoriatic arthritis" ;
                    rdfs:label "psoriatic arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispsoriaticArthropathy
:psoriaticArthropathy rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Indication ;
                      OpenPVSignal:has_ICD_code "L4052" ;
                      OpenPVSignal:has_MedDRA_code 10037162 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Psoriatic arthropathy" ;
                      rdfs:label "psoriatic arthropathy" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispublished_studies
:published_studies rdf:type owl:NamedIndividual ,
                            obo:OAE_0001197 ;
                   OpenPVSignal:refers_to_adverse_effect :psoriasis ,
                                                         :psoriasisAggravated ;
                   OpenPVSignal:refers_to_drug :tocilizumab ;
                   mp:references :ref10 ,
                                 :ref11 ,
                                 :ref12 ;
                   OpenPVSignal:has_content "There are three published articles describing psoriasis or aggravated psoriasis occurring in four patients during tocilizumab use (Table 3).10-12 The indications were psoriatic and non-psoriatic. One young man also experienced a flare of pre-existing uveitis. The form of psoriasis was palmoplantar in one patient and guttate in another, in keeping with observations in the VigiBase ICSRs. Two patients recovered on dechallenge and one relapsed on rechallenge. However, this patient and one other tolerated further administrations while using topical psoriasis treatment." ;
                   rdfs:label "published studies" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispustularPsoriasis
:pustularPsoriasis rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "L401" ;
                   OpenPVSignal:has_MedDRA_code 10037575 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Pustular psoriasis" ;
                   rdfs:label "pustular psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasispvSingal
:pvSingal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :Discussion_and_Conclusion ,
                                                   :Reports_in_VigiBase ,
                                                   :psoriasis_pathophysiology ;
          OpenPVSignal:is_supported_by_individual_case_report :LiteraturePsoriasisPatient1 ,
                                                              :LiteraturePsoriasisPatient2 ,
                                                              :LiteraturePsoriasisPatient3 ,
                                                              :LiteraturePsoriasisPatient4 ,
                                                              :ReportAgg.Psoriasis1 ,
                                                              :ReportAgg.Psoriasis2 ,
                                                              :ReportAgg.Psoriasis3 ,
                                                              :ReportAgg.Psoriasis4 ,
                                                              :ReportAgg.Psoriasis5 ,
                                                              :ReportAgg.Psoriasis6 ,
                                                              :ReportAgg.Psoriasis7 ,
                                                              :ReportAgg.Psoriasis8 ,
                                                              :ReportPsoriasis1 ,
                                                              :ReportPsoriasis10 ,
                                                              :ReportPsoriasis11 ,
                                                              :ReportPsoriasis12 ,
                                                              :ReportPsoriasis2 ,
                                                              :ReportPsoriasis3 ,
                                                              :ReportPsoriasis4 ,
                                                              :ReportPsoriasis5 ,
                                                              :ReportPsoriasis6 ,
                                                              :ReportPsoriasis7 ,
                                                              :ReportPsoriasis8 ,
                                                              :ReportPsoriasis9 ;
          OpenPVSignal:is_supported_by_statistical_entity :IC025ForTocilizumabAndPsoriasis ,
                                                          :IC025ForTocilizumabAndPsoriasisAggravated ,
                                                          :ICForTocilizumabAndPsoriasis ,
                                                          :ICForTocilizumabAndPsoriasisAggravated ,
                                                          :ReportsInVigibaseForPsoriasisAndTocilizumab ,
                                                          :incidenceOfInflammatoryArthropathyInPsoriasisPatients ,
                                                          :incidence_of_psoriasis ,
                                                          :reportInVigibaseForPsoriasisAggravatedAndTocilizumab ,
                                                          :report_in_vigibase_for_psoriasis_aggravated_and_tocilizumab_age_info ,
                                                          :reportsInVigibaseForTocilizumab ,
                                                          :reports_with_juvenile_arthritis ,
                                                          :reports_with_psoriatic_arthropathy ,
                                                          :reports_with_seronegative_RA ,
                                                          :reports_with_time_to_onset_info_in_agg_psoriasis_group ,
                                                          :reports_with_time_to_onset_info_in_psoriasis_group ,
                                                          <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reportsInVigibaseForPsoriasis&PsoriasisAggravated> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reports_in_vigibase_for_psoriasis_&_psoriasis_aggravated_age_info> ;
          OpenPVSignal:refers_to_adverse_effect :psoriasis ,
                                                :psoriasisAggravated ;
          OpenPVSignal:refers_to_drug :tocilizumab ;
          mp:supportedByData :TNF_inhibitors_and_psoriasis ,
                             :psoriasis_associated_with_antirhematoid_agents ,
                             :published_studies ;
          OpenPVSignal:initially_identified_on "01/05/2014" ;
          rdfs:label "pv singal" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisrebamipide
:rebamipide rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A02BX14" ;
            rdfs:label "rebamipide" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisrecommended_dosage
:recommended_dosage rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Dosage ;
                    OpenPVSignal:refers_to_drug :tocilizumab ;
                    mp:references :ref8 ;
                    OpenPVSignal:has_content "The recommended dose and dose frequency of tocilizumab is 8 mg/kg monthly for adults with RA and 8 mg/kg two weekly for children weighing more than 30 kg with systemic JIA. Exceeding a dose of 800 mg is not recommended." ;
                    rdfs:label "recommended dosage" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref1
:ref1 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "Blauvelt A, Ehst BD. Pathophysiology of psoriasis. UpToDate. URL: http://www.uptodate.com/contents/pathophysiolo gy-of-psoriasis. Accessed: September 2013." ;
      rdfs:label "ref1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref10
:ref10 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Laurent S, Le Parc JM, Clérici T, Bréban M, Mahé E. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol. 2010;136:1364- 5." ;
       rdfs:label "ref10" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref11
:ref11 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Wendling D, Letho-Gyselinck H, Guillot X, Prati C. Psoriasis onset with tocilizumab treatment for rheuma- toid arthritis. J Rheumatol. 2012;39:657." ;
       rdfs:label "ref11" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref12
:ref12 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Lekpa FK, Poulain C, Wendling D, Soubrier M, De Bandt M, Berthelot JM et al. Is IL-6 an appropriate target to treat spondyloarthritispatients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther. 2012;14:R53." ;
       rdfs:label "ref12" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref13
:ref13 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun. 2011;37:273-88." ;
       rdfs:label "ref13" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref2
:ref2 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "Feldman SR. Epidemiology, clinical manifestations and diagnosis of psoriasis. URL: http://www.uptodate.com/ contents/epidemiology-clinical-manifestations-and-diag- nosis-of-psoriasis. Accessed: September 2013." ;
      rdfs:label "ref2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref3
:ref3 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "British Association of Dermatologists. Psoriasis- an Overview.URL: http://www.bad.org.uk/site/864/ Default.aspx. Accessed: September 2013." ;
      rdfs:label "ref3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref4
:ref4 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "DermNet NZ. URL: http://www.dermnetnz.org/scaly/psoriasis- general.html. Accessed: September 2013." ;
      rdfs:label "ref4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref5
:ref5 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "Stone JH. Overview of biologic agents in the rheumatic diseases. UptoDate. URL: http://www.uptodate.com/contents/overview-of-biologic-agents-in-the-rheumatic-diseases. Accessed: 18 June 2013." ;
      rdfs:label "ref5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref6
:ref6 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "FDA. Information for Healthcare Professionals: Tumor Necrosis Factor (TNF) Blockers. URL: http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm174474.htm. Accessed: 18 June 2013." ;
      rdfs:label "ref6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref7
:ref7 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "Orencia. Bristol-Myers Squibb PharmaEEIG URL: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_- Product_Information/human/000701/ WC500048935.pdf. Accessed: 2 July 2013." ;
      rdfs:label "ref7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref8
:ref8 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "RoActemra. Roche Registration Ltd. URL: http:// www.ema.europa.eu/docs/en_GB/document_librar y/ EPAR_-_Product_Information/human/000955/ WC500054890.pdf. Accessed: 2 July 2013." ;
      rdfs:label "ref8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisref9
:ref9 rdf:type owl:NamedIndividual ,
               OpenPVSignal:Bibliographic_reference ;
      OpenPVSignal:has_content "Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-15." ;
      rdfs:label "ref9" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisreportInVigibaseForPsoriasisAggravatedAndTocilizumab
:reportInVigibaseForPsoriasisAggravatedAndTocilizumab rdf:type owl:NamedIndividual ,
                                                               OpenPVSignal:Reports_group ;
                                                      OpenPVSignal:is_subgroup_of <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reportsInVigibaseForPsoriasis&PsoriasisAggravated> ;
                                                      OpenPVSignal:refers_to_adverse_effect :psoriasisAggravated ;
                                                      OpenPVSignal:refers_to_drug :tocilizumab ;
                                                      OpenPVSignal:has_count 8 ;
                                                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                      rdfs:label "reports in vigibase for psoriasis aggravated and tocilizumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisreport_in_vigibase_for_psoriasis_aggravated_and_tocilizumab_age_info
:report_in_vigibase_for_psoriasis_aggravated_and_tocilizumab_age_info rdf:type owl:NamedIndividual ,
                                                                               OpenPVSignal:Reports_group ;
                                                                      OpenPVSignal:is_subgroup_of :reportInVigibaseForPsoriasisAggravatedAndTocilizumab ;
                                                                      OpenPVSignal:has_count 7 ;
                                                                      OpenPVSignal:has_max_age 58 ;
                                                                      OpenPVSignal:has_median_age 51 ;
                                                                      OpenPVSignal:has_min_age 39 ;
                                                                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                      rdfs:label "reports in vigibase for psoriasis aggravated and tocilizumab age info" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisreportsInVigibaseForTocilizumab
:reportsInVigibaseForTocilizumab rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:refers_to_drug :tocilizumab ;
                                 OpenPVSignal:has_count 3796 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "reports in vigibase for tocilizumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisreports_with_juvenile_arthritis
:reports_with_juvenile_arthritis rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:concerns_indication_for_use :juvenileArthritis ;
                                 OpenPVSignal:is_subgroup_of :ReportsInVigibaseForPsoriasisAndTocilizumab ;
                                 OpenPVSignal:has_count 1 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "reports with juvenile arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisreports_with_psoriatic_arthropathy
:reports_with_psoriatic_arthropathy rdf:type owl:NamedIndividual ,
                                             OpenPVSignal:Reports_group ;
                                    OpenPVSignal:concerns_indication_for_use :psoriaticArthropathy ;
                                    OpenPVSignal:is_subgroup_of :reportInVigibaseForPsoriasisAggravatedAndTocilizumab ;
                                    OpenPVSignal:has_count 2 ;
                                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                    rdfs:label "reports with psoriatic arthropathy" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisreports_with_seronegative_RA
:reports_with_seronegative_RA rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Reports_group ;
                              OpenPVSignal:concerns_indication_for_use :seronegativeRheumatoidArthritis ;
                              OpenPVSignal:is_subgroup_of :reportInVigibaseForPsoriasisAggravatedAndTocilizumab ;
                              OpenPVSignal:has_count 1 ;
                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                              rdfs:label "reports with seronegative RA" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisreports_with_time_to_onset_info_in_agg_psoriasis_group
:reports_with_time_to_onset_info_in_agg_psoriasis_group rdf:type owl:NamedIndividual ,
                                                                 OpenPVSignal:Reports_group ;
                                                        OpenPVSignal:is_subgroup_of :reportInVigibaseForPsoriasisAggravatedAndTocilizumab ;
                                                        OpenPVSignal:time_to_onset :time_to_onset_info_for_agg_psoriasis ;
                                                        OpenPVSignal:has_count 6 ;
                                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                        rdfs:label "reports with time to onset info in agg psoriasis group" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisreports_with_time_to_onset_info_in_psoriasis_group
:reports_with_time_to_onset_info_in_psoriasis_group rdf:type owl:NamedIndividual ,
                                                             OpenPVSignal:Reports_group ;
                                                    OpenPVSignal:is_subgroup_of :ReportsInVigibaseForPsoriasisAndTocilizumab ;
                                                    OpenPVSignal:time_to_onset :time_to_onset_info_for_psoriasis ;
                                                    OpenPVSignal:has_count 4 ;
                                                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                    rdfs:label "reports with time to onset info in psoriasis group" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisrheumatoidArthritis
:rheumatoidArthritis rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Indication ;
                     OpenPVSignal:has_ICD_code "M069" ;
                     OpenPVSignal:has_MedDRA_code 10039073 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Rheumatoid arthritis" ;
                     rdfs:label "rheumatoid arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisrituximab
:rituximab rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_mechanism :Proposed_mechanism_for_psoriasis_due_to_tocilizumab ;
           OpenPVSignal:has_ATC_code "L01XC02" ;
           rdfs:label "rituximab" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisseronegativeRheumatoidArthritis
:seronegativeRheumatoidArthritis rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Indication ;
                                 OpenPVSignal:has_ICD_code "M069" ;
                                 OpenPVSignal:has_MedDRA_code 10062719 ;
                                 OpenPVSignal:has_MedDRA_prefered_term "Seronegative rheumatoid arthritis" ;
                                 rdfs:label "seronegative rheumatoid arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasissulphasalazine
:sulphasalazine rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "A07EC01" ;
                rdfs:label "sulphasalazine" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasissummary
:summary rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Summary ;
         OpenPVSignal:has_content "Tocilizumab inhibits the activity of the inflammatory cytokine interleukin (IL)-6. Its indications include rheumatoid arthritis and juvenile idiopathic arthritis. In the second quarter of 2013, after exclusion of three duplicates, the WHO Global Individual Case Safety Report (ICSR) Database, VigiBase® held 20 ICSRs of new onset or aggravated psoriasis attributed to tocilizumab. Four published case reports were also identified. This suspected reaction is paradoxical since psoriasis is an autoimmune inflammatory disease primarily affecting the skin. When the published case reports together with VigiBase ICSRs for tocilizumab were combined, there was evidence of improvement with tocilizumab discontinuation or recurrence with each administration in four reports. Report characteristics indicate that there are similarities between reports of psoriasis occurring with tocilizumab and those occurring with TNF inhibitors which have been well- documented in the literature. The VigiBase ICSRs provide additional evidence to the published case histories for tocilizumab." ;
         rdfs:label "summary" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasissweating
:sweating rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10042661 ;
          OpenPVSignal:has_MedDRA_prefered_term "Sweating" ;
          rdfs:label "sweating" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasistelmisartan
:telmisartan rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "C09CA07" ,
                                       "C09DA07" ,
                                       "C09DB04" ;
             rdfs:label "telmisartan" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisthyroxine
:thyroxine rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "H03AA01" ;
           rdfs:label "thyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisticlopidine
:ticlopidine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "B01AC05" ;
             rdfs:label "ticlopidine" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasistime_to_onset_info_for_agg_psoriasis
:time_to_onset_info_for_agg_psoriasis rdf:type owl:NamedIndividual ,
                                               <http://www.w3.org/2006/time#DurationDescription> ;
                                      OpenPVSignal:has_content "5 to 191 days, median 84 days, for the aggravated psoriasis group (six patients)." ;
                                      rdfs:label "time to onset info for agg psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasistime_to_onset_info_for_psoriasis
:time_to_onset_info_for_psoriasis rdf:type owl:NamedIndividual ,
                                           <http://www.w3.org/2006/time#DurationDescription> ;
                                  OpenPVSignal:has_content "The duration of tocilizumab use to onset of psoriasis was 1 to 85 days, median 19 days, for the psoriasis group (four patients)" ;
                                  rdfs:label "time to onset info for psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasistnfInhibitors
:tnfInhibitors rdf:type owl:NamedIndividual ,
                        OpenPVSignal:DrugClass ;
               OpenPVSignal:has_mechanism :Proposed_mechanism_for_psoriasis_due_to_tocilizumab ;
               OpenPVSignal:has_ATC_code "L04AB" ;
               rdfs:label "tnf inhibitors" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasistocilizumab
:tocilizumab rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_mechanism :Mechanism_of_Tocilizumab ,
                                        :Proposed_mechanism_for_psoriasis_due_to_tocilizumab ;
             OpenPVSignal:has_ATC_code "L04AC07" ;
             rdfs:label "tocilizumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_agg_psoriasis_1
:usage_for_report_agg_psoriasis_1 rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Drug_Usage ;
                                  OpenPVSignal:concerns_indication_for_use :seronegativeRheumatoidArthritis ;
                                  OpenPVSignal:refers_to_dosage :AggPsoriasisDosage1 ;
                                  OpenPVSignal:refers_to_drug :tocilizumab ;
                                  rdfs:label "usage for report agg psoriasis 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_agg_psoriasis_2
:usage_for_report_agg_psoriasis_2 rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Drug_Usage ;
                                  OpenPVSignal:concerns_indication_for_use :psoriaticArthritis ;
                                  OpenPVSignal:refers_to_dosage :AggPsoriasisDosage2 ;
                                  OpenPVSignal:refers_to_drug :tocilizumab ;
                                  rdfs:label "usage for report agg psoriasis 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_agg_psoriasis_3
:usage_for_report_agg_psoriasis_3 rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Drug_Usage ;
                                  OpenPVSignal:refers_to_dosage :AggPsoriasisDosage3 ;
                                  OpenPVSignal:refers_to_drug :tocilizumab ;
                                  rdfs:label "usage for report agg psoriasis 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_agg_psoriasis_4
:usage_for_report_agg_psoriasis_4 rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Drug_Usage ;
                                  OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                                  OpenPVSignal:refers_to_dosage :AggPsoriasisDosage4 ;
                                  OpenPVSignal:refers_to_drug :tocilizumab ;
                                  rdfs:label "usage for report agg psoriasis 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_agg_psoriasis_5
:usage_for_report_agg_psoriasis_5 rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Drug_Usage ;
                                  OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                                  OpenPVSignal:refers_to_drug :tocilizumab ;
                                  rdfs:label "usage for report agg psoriasis 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_agg_psoriasis_6
:usage_for_report_agg_psoriasis_6 rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Drug_Usage ;
                                  OpenPVSignal:concerns_indication_for_use :psoriaticArthropathy ;
                                  OpenPVSignal:refers_to_drug :tocilizumab ;
                                  rdfs:label "usage for report agg psoriasis 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_agg_psoriasis_7
:usage_for_report_agg_psoriasis_7 rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Drug_Usage ;
                                  OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                                  OpenPVSignal:refers_to_dosage :AggPsoriasisDosage7 ;
                                  OpenPVSignal:refers_to_drug :tocilizumab ;
                                  rdfs:label "usage for report agg psoriasis 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_agg_psoriasis_8
:usage_for_report_agg_psoriasis_8 rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Drug_Usage ;
                                  OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                                  OpenPVSignal:refers_to_dosage :AggPsoriasisDosage8 ;
                                  OpenPVSignal:refers_to_drug :tocilizumab ;
                                  rdfs:label "usage for report agg psoriasis 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_literature_1
:usage_for_report_literature_1 rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Drug_Usage ;
                               OpenPVSignal:concerns_indication_for_use <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#still’sDisease> ;
                               OpenPVSignal:refers_to_dosage :LiteraturePsoriasisDosage1 ;
                               OpenPVSignal:refers_to_drug :tocilizumab ;
                               rdfs:label "usage for report literature 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_literature_2
:usage_for_report_literature_2 rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Drug_Usage ;
                               OpenPVSignal:concerns_indication_for_use :psoriaticArthritis ;
                               OpenPVSignal:refers_to_dosage :LiteraturePsoriasisDosage2 ;
                               OpenPVSignal:refers_to_drug :tocilizumab ;
                               rdfs:label "usage for report literature 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_literature_3
:usage_for_report_literature_3 rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Drug_Usage ;
                               OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                               OpenPVSignal:refers_to_dosage :LiteraturePsoriasisDosage3 ;
                               OpenPVSignal:refers_to_drug :tocilizumab ;
                               rdfs:label "usage for report literature 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_literature_4
:usage_for_report_literature_4 rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Drug_Usage ;
                               OpenPVSignal:concerns_indication_for_use :ankylosingSpondylitis ,
                                                                        :uveitis ;
                               OpenPVSignal:refers_to_dosage :LiteraturePsoriasisDosage4 ;
                               OpenPVSignal:refers_to_drug :tocilizumab ;
                               rdfs:label "usage for report literature 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_1
:usage_for_report_psoriasis_1 rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Drug_Usage ;
                              OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              rdfs:label "usage for report psoriasis 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_10
:usage_for_report_psoriasis_10 rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Drug_Usage ;
                               OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                               OpenPVSignal:refers_to_dosage :PsoriasisPatientsDosage10 ;
                               OpenPVSignal:refers_to_drug :tocilizumab ;
                               rdfs:label "usage for report psoriasis 10" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_12
:usage_for_report_psoriasis_12 rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Drug_Usage ;
                               OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                               OpenPVSignal:refers_to_dosage :PsoriasisPatientsDosage12 ;
                               OpenPVSignal:refers_to_drug :tocilizumab ;
                               rdfs:label "usage for report psoriasis 12" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_2
:usage_for_report_psoriasis_2 rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Drug_Usage ;
                              OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                              OpenPVSignal:refers_to_dosage :PsoriasisPatientsDosage2 ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              rdfs:label "usage for report psoriasis 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_3
:usage_for_report_psoriasis_3 rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Drug_Usage ;
                              OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                              OpenPVSignal:refers_to_dosage :PsoriasisPatientsDosage3 ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              rdfs:label "usage for report psoriasis 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_5
:usage_for_report_psoriasis_5 rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Drug_Usage ;
                              OpenPVSignal:concerns_indication_for_use :juvenileArthritis ;
                              OpenPVSignal:refers_to_dosage :PsoriasisPatientsDosage5 ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              rdfs:label "usage for report psoriasis 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_6
:usage_for_report_psoriasis_6 rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Drug_Usage ;
                              OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                              OpenPVSignal:refers_to_dosage :PsoriasisPatientsDosage6 ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              rdfs:label "usage for report psoriasis 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_7
:usage_for_report_psoriasis_7 rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Drug_Usage ;
                              OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                              OpenPVSignal:refers_to_dosage :PsoriasisPatientsDosage7 ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              rdfs:label "usage for report psoriasis 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_8
:usage_for_report_psoriasis_8 rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Drug_Usage ;
                              OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                              OpenPVSignal:refers_to_dosage :PsoriasisPatientsDosage8 ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              rdfs:label "usage for report psoriasis 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisusage_for_report_psoriasis_9
:usage_for_report_psoriasis_9 rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Drug_Usage ;
                              OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                              OpenPVSignal:refers_to_drug :tocilizumab ;
                              rdfs:label "usage for report psoriasis 9" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisuveitis
:uveitis rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Indication ;
         OpenPVSignal:has_ICD_code "H44139" ;
         OpenPVSignal:has_MedDRA_code 10046851 ;
         OpenPVSignal:has_MedDRA_prefered_term "Uveitis" ;
         rdfs:label "uveitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasisweek_interval
:week_interval rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "weeks" ;
               <http://www.w3.org/2006/time#numericPosition> 1 ;
               rdfs:label "week interval" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#hydrochlorothiazide_/_valsartan
<http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#hydrochlorothiazide_/_valsartan> rdf:type owl:NamedIndividual ,
                                                                                                                                  OpenPVSignal:Drug ;
                                                                                                                         OpenPVSignal:has_ATC_code "C03AA03" ,
                                                                                                                                                   "C09CA03" ;
                                                                                                                         rdfs:label "hydrochlorothiazide / valsartan" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reportsInVigibaseForPsoriasis&PsoriasisAggravated
<http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reportsInVigibaseForPsoriasis&PsoriasisAggravated> rdf:type owl:NamedIndividual ,
                                                                                                                                                    OpenPVSignal:Reports_group ;
                                                                                                                                           OpenPVSignal:refers_to_adverse_effect :psoriasis ,
                                                                                                                                                                                 :psoriasisAggravated ;
                                                                                                                                           OpenPVSignal:refers_to_drug :tocilizumab ;
                                                                                                                                           OpenPVSignal:has_count 20 ;
                                                                                                                                           OpenPVSignal:has_count_of_men 4 ;
                                                                                                                                           OpenPVSignal:has_count_of_women 15 ;
                                                                                                                                           OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                                           rdfs:label "overall reports in vigibase for psoriasis & psoriasis aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reports_in_vigibase_for_psoriasis_&_psoriasis_aggravated_age_info
<http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reports_in_vigibase_for_psoriasis_&_psoriasis_aggravated_age_info> rdf:type owl:NamedIndividual ,
                                                                                                                                                                    OpenPVSignal:Reports_group ;
                                                                                                                                                           OpenPVSignal:is_subgroup_of <http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#reportsInVigibaseForPsoriasis&PsoriasisAggravated> ;
                                                                                                                                                           OpenPVSignal:has_count 10 ;
                                                                                                                                                           OpenPVSignal:has_max_age 60 ;
                                                                                                                                                           OpenPVSignal:has_min_age 33 ;
                                                                                                                                                           OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                                                           rdfs:label "reports in vigibase for psoriasis & psoriasis aggravated age info" .


###  http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#still’sDisease
<http://purl.org/OpenPVSignal/Signals/2014_2_tocilizumab_psoriasis_aggravated_psoriasis#still’sDisease> rdf:type owl:NamedIndividual ,
                                                                                                                 OpenPVSignal:Indication ;
                                                                                                        OpenPVSignal:has_MedDRA_code 10042061 ;
                                                                                                        OpenPVSignal:has_MedDRA_prefered_term "Still's disease" ;
                                                                                                        rdfs:label "Still's disease" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
